Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
A phase 1/2 trial of JDQ443, Trametinib, Ribociclib in non-small-cell lung cancer and small-cell lung cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05358249 by Novartis Pharmaceuticals, with 74 participants enrolled, started 2022-10-24 and due to reach its primary completion in 2026-09-30. Interventions recorded: JDQ443, trametinib, Ribociclib, cetuximab. Conditions listed: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other
Shares JDQ443, Trametinib, Cetuximab, Novartis.
- TrialStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Shares JDQ443, Novartis, Non-small-cell lung cancer.
- TrialStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Shares Ribociclib, Novartis, Small-cell lung cancer.
- TrialStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Shares Trametinib, Ribociclib, Novartis.
- TrialStudy of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Shares JDQ443, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Cetuximab, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
- TrialStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares JDQ443, Colorectal cancer, Non-small-cell lung cancer.
- PersonDongsheng Tu
Shares Cetuximab, Colorectal cancer, Non-small-cell lung cancer.